Results 11 to 20 of about 6,146 (182)

Empagliflozin Induces White Adipocyte Browning and Modulates Mitochondrial Dynamics in KK Cg-Ay/J Mice and Mouse Adipocytes

Frontiers in Physiology, 2021
Background: White adipose tissue (WAT) browning is a promising target for obesity prevention and treatment. Empagliflozin has emerged as an agent with weight-loss potential in clinical and in vivo studies, but the mechanisms underlying its effect are not
Linxin Xu, Linxin Xu, Chaofei Xu, Xiangyang Liu, Xiaoyu Li, Ting Li, Xiaochen Yu, Mei Xue, Jing Yang, Constantine E. Kosmas, Dimitrios Moris, Fabian Sanchis-Gomar, Naofumi Yoshida, Nathan A. Berger, Wilbert S. Aronow, Bei Sun, Liming Chen   +16 more
doaj   +1 more source

Empagliflozin: a potential anticancer drug

Discover Oncology, 2023
Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a highly effective and well-tolerated antidiabetic drug. In addition to hypoglycemic effects, empagliflozin has many other effects, such as being hypotensive and cardioprotective.
Wenwen Wu, Yanyan Wang, Jun Xie, Shaohua Fan   +3 more
doaj   +1 more source

Association between Empagliflozin Use and Electrocardiographic Changes

Clinics and Practice, 2022
Empagliflozin, a sodium-glucose transporter 2 inhibitor, has been shown to bind to late sodium channels in mice cardiomyocytes. We sought to investigate the electrocardiographic (ECG) features associated with empagliflozin use in patients with diabetes ...
Daniel Antwi-Amoabeng, Sunil Sathappan, Bryce D. Beutler, Mark B. Ulanja, Munadel Awad, Nageshwara Gullapalli, Phillip Duncan, T. David Gbadebo   +7 more
doaj   +1 more source

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

Frontiers in Pharmacology, 2022
The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in patients with Type 2 Diabetes Mellitus (T2DM)) trial evidenced the potential of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of patients with diabetes and ...
Alana Aragón-Herrera, Alana Aragón-Herrera, Manuel Otero-Santiago, Laura Anido-Varela, Sandra Moraña-Fernández, Manuel Campos-Toimil, Tomás García-Caballero, Luis Barral, Estefanía Tarazón, Estefanía Tarazón, Esther Roselló-Lletí, Esther Roselló-Lletí, Manuel Portolés, Manuel Portolés, Oreste Gualillo, Isabel Moscoso, Ricardo Lage, José Ramón González-Juanatey, José Ramón González-Juanatey, Sandra Feijóo-Bandín, Sandra Feijóo-Bandín, Francisca Lago, Francisca Lago   +22 more
doaj   +1 more source

Investigating the Role of Empagliflozin in the Pathological Progress of Ischemia-Reperfusion Injury in Rat Kidneys: The Involvement of Nitric Oxide [PDF]

Advanced Pharmaceutical Bulletin
Purpose: Renal ischemia-reperfusion (RIR) is a pathological condition that can lead to severe outcomes due to damage to kidney structures. Additionally, oxidative stress is triggered by mitochondrial disruption during reperfusion, potentially resulting ...
Amin Hasanvand, Abdolreza Tajdar, Azita Zafar Mohtashami, Zahra Haghighatian, Elham Goodarzi, Peyman Amanolahi Baharvand, Babak Hadian   +6 more
doaj   +1 more source

Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways

Journal of Immunology Research, 2021
Background. Sodium-glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitors are glucose-lowering drugs whose anti-inflammatory properties have recently become useful in tackling metabolic syndromes in chronic inflammatory diseases ...
Nami Lee, Yu Jung Heo, Sung-E Choi, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Yup Kang, Kwan Woo Lee, Hae Jin Kim   +8 more
doaj   +1 more source

Dapagliflozin versus empagliflozin in patients with chronic kidney disease

Frontiers in Pharmacology, 2023
Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving outcomes in CKD patients is unestablished.
Hilmi Alnsasra, Hilmi Alnsasra, Gal Tsaban, Gal Tsaban, Adam Solomon, Fouad Khalil, Enis Aboalhasan, Abed N. Azab, Abed N. Azab, Joseph Azuri, Joseph Azuri, Ariel Hammerman, Ronen Arbel   +12 more
doaj   +1 more source

Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study.

PLoS ONE, 2022
Patients with type 2 diabetes who have cardiovascular disease and are receiving empagliflozin have a lower rate of primary composite cardiovascular outcomes.
Haruka Tamura, Yoshinobu Kondo, Kohei Ito, Masanori Hasebe, Shinobu Satoh, Yasuo Terauchi   +5 more
doaj   +1 more source

Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice

iScience, 2023
Summary: Obesity has become a global epidemic, associated with several chronic complications. The intestinal microbiome is a critical regulator of metabolic homeostasis and obesity.
Junfeng Shi, Hongyan Qiu, Qian Xu, Yuting Ma, Tongtong Ye, Zengguang Kuang, Na Qu, Chengxia Kan, Ningning Hou, Fang Han, Xiaodong Sun   +10 more
doaj   +1 more source

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. [PDF]

PLoS ONE, 2017
Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associated with slower progression of diabetic kidney disease.
David Cherney, Bruce A Perkins, Yuliya Lytvyn, Hiddo Heerspink, María E Rodríguez-Ortiz, Harald Mischak   +5 more
doaj   +1 more source